It may be recollected that Medical Devices Industry had been inconvenienced following discontinuity of allowing India Specific Labelling after imports. Rather it was directed that all products should be labelled before imports.
This Comprehensive notification from Government of India was urgently needed since the Interim Relief granted in March 2014 by DCGI was to expire in September 2014 and was brought to the notice of Ministry of Health & Family welfare and to DCG(I) by FICCI Medical Device Forum members.
FICCI Medical Device Forum along with others particularly took up the issue of India specific labelling with the urgency for addressing the sector's needs comprehensively with MOH&FW as well as with DCG(I) which supported the current amendment of the Drug & Cosmetic Rules, to allow India specific labelling after imports of Medical Devices into India.
It comes as a big relief to the sector and ushers in a positive sentiment amongst the Industry. The new notification is well timed as it will enable affordability and continued supply of Medical Devices to needy patients and healthcare providers.
Mr. Sushobhan Dasgupta, Chairman, FICCI Medical Devices Forum and Managing Director, Johnson & Johnson Medical India said, CDSCO has been a strong pillar of support and guidance for the growth of the medical devices industry in India. Their decision on this import labelling issue is a great example of their continued encouragement and sound understanding of the issues faced by the industry. He also added, We strongly believe that the Indian drugs & devices regulatory agencies are doing a commendable job of effectively monitoring the quality of medical devices and in-vitro diagnostics products imported into or manufactured and sold in India.
FICCI comprises both Indian and multinational manufacturers of global repute, who, for many past years, worked in close collaboration with the Indian regulatory agencies. The Indian drugs and medical devices regulatory agencies have ensured that the medical devices and in-vitro diagnostic products which are manufactured or imported and sold in the country, continue to benefit the patients who need them and are used in the most appropriate, effective and safe way.
Powered by Capital Market - Live News
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
